This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
News|Articles|June 3, 2010
Regulatory Roundup: USP and Russia's Roszdravnadzor Sign MOU
Author(s)Pharmaceutical Technology Editors
Regulatory Roundup: USP and Russia's Roszdravnadzor Sign MOU
Advertisement
The US Pharmacopeia (USP) and Russia’s Roszdravnadzor, the federation’s regulatory healthcare agency, signed a memorandum of understanding in April 2009 to work toward protecting and improving the quality of medicines. As part of the agreement, USP announced on June 1, 2010, that it has completed a series of eight drug quality courses at Moscow’s Scientific Center for Expertise of Medical Products. Approximately 100 Russian laboratory specialists attended the workshops.
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement